Shavit Capital

MeMed Diagnostics is a personalized diagnostics company founded in 2009. They are here to improve patient care, empower physicians, and lower health-care costs through rapid and actionable diagnostics for infectious diseases. Their main focus is preventing antibiotics misuse. Antibiotics are the most prescribed class of drugs worldwide with a global market of 25-30 billion $US. Up to 70% of antibiotics are estimated to be prescribed inappropriately, making them the most misused drug class in the world. Antibiotics misuse leads to ineffective treatment, emergence of resistant strains of bacteria, and is estimated to cost healthcare systems worldwide tens of billions of dollars annually. Their platform, the ImmunoDx™, leverages the world’s most accurate diagnostic system for differentiating bacteria from viruses, crafted by nature, the body’s immune system. ImmunoDx™ combines proprietary biomarkers, algorithms, and clinical know-how to identify the source of infection (virus vs bacteria, bacterial spectrum), by decoding the immune system`s differential response to different pathogens. This unique approach enables ImmunoDx™ to address some of the major challenges facing currently available diagnostics for infectious diseases.

Lightricks develops creativity tools that enable its users to craft and share visual content on mobile devices. Lightricks integrates advanced technologies from computer vision, computer graphics, and image processing into mobile products. Lightricks' products include Facetune, Facetune 2, Enlight, Enlight Photofox, Enlight Videoleap, and Enlight Quickshot. Lightricks was founded in January 2013 by five entrepreneurs with comprehensive knowledge in the fields of computer graphics, image processing, machine learning, and artificial intelligence, who left promising careers in order to realize their dream.

KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Veev is a building technology company that reinvents the way homes are built and experienced. Veev's home operating system creates room-specific lighting, shade, and climate control and also offers protection against intrusion and cybercrime, thereby providing clients a one-stop solution to all their smart housing requirements. Key components of the Veev panelized building system include the use of light gauge steel (LGS) for framing; high performance acrylic (HPA) for surfaces and millwork; radiant climate control systems; and a digital home ecosystem. The company is focused currently on high-performance multifamily and accessory dwelling unit (ADU) products. The current development pipeline totals more than 230 units and 620,000 gross building square feet.

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University. Since then, numerous preclinical trials have found the technology to be effective and safe for various indications and anatomic areas. The findings were published in 12 papers in peer-reviewed scientific journals. Today, the company is running its first clinical trial with very promising preliminary results.

Syqe Medical aims to transform cannabis and other psychoactive botanicals into mainstream medical drugs. It works to decentralize drug development. Syqe Medical is based in Tel Aviv, Israel.

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed in 2003 at Tel Aviv University. Since then, numerous preclinical trials have found the technology to be effective and safe for various indications and anatomic areas. The findings were published in 12 papers in peer-reviewed scientific journals. Today, the company is running its first clinical trial with very promising preliminary results.

Anchiano is a biopharmaceutical company that specializes in the development of Targeted Cancer Therapies for the treatment of numerous types of cancer. The Company's technology offers a safe and long-term treatment of cancer, with no adverse effects. BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 25 years. The drug candidates developed by the Company are targeted and their goal is to selectively destroy the cancer cells without affecting healthy cells (‘Targeted Cancer Therapy'). The approach is based on the identification of target genes, such as H19, that are expressed only in cancerous tumors, and not in healthy cells, and on the use of those genes' regulatory sequences for the activation of a toxin inside the cancerous cells only, thus destroying them without harming healthy cells. BioCancell's leading drug candidate, BC-819, has completed a Phase IIb clinical trial for the treatment of bladder cancer, as well as additional clinical trials for other cancer indications. BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuation of the success of pre-clinical studies that have examined the use of BC-821 as a treatment for several cancer indications

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

PolyPid is a development stage company that has developed a platform technology for the healthcare industry that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). PolyPid’s technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. PolyPid allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate (zero-order kinetics). The flexibility of this innovative technology enables local administration of compounds across numerous therapeutic classes for several applications.

Mapi Pharma is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets. Mapi is built on strong chemical and pharmaceutical R&D capabilities, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it operates. Mapi is dedicated to providing generic and innovative intermediates and APIs, as well as developing finished dosage forms – either for Mapi’s internal API program, as a vertically integrated company, or as generics of leading brands. Mapi is headquartered in Israel. It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel’s designated chemical park. Mapi has a strong IP position, filing numerous patent applications for APIs and formulations.